Inhibition of angiogenesis by interleukin 4

Interleukin (IL)-4, a crucial modulator of the immune system and an active antitumor agent, is also a potent inhibitor of angiogenesis. When incorporated at concentrations of 10 ng/ml or more into pellets implanted into the rat cornea or when delivered systemically to the mouse by intraperitoneal in...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of experimental medicine Vol. 188; no. 6; pp. 1039 - 1046
Main Authors Volpert, O V, Fong, T, Koch, A E, Peterson, J D, Waltenbaugh, C, Tepper, R I, Bouck, N P
Format Journal Article
LanguageEnglish
Published United States The Rockefeller University Press 21.09.1998
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Interleukin (IL)-4, a crucial modulator of the immune system and an active antitumor agent, is also a potent inhibitor of angiogenesis. When incorporated at concentrations of 10 ng/ml or more into pellets implanted into the rat cornea or when delivered systemically to the mouse by intraperitoneal injection, IL-4 blocked the induction of corneal neovascularization by basic fibroblast growth factor. IL-4 as well as IL-13 inhibited the migration of cultured bovine or human microvascular cells, showing unusual dose-response curves that were sharply stimulatory at a concentration of 0.01 ng/ml but inhibitory over a wide range of higher concentrations. Recombinant cytokine from mouse and from human worked equally well in vitro on bovine and human endothelial cells and in vivo in the rat, showing no species specificity. IL-4 was secreted at inhibitory levels by activated murine T helper (TH0) cells and by a line of carcinoma cells whose tumorigenicity is known to be inhibited by IL-4. Its ability to cause media conditioned by these cells to be antiangiogenic suggested that the antiangiogenic activity of IL-4 may play a role in normal physiology and contribute significantly to its demonstrated antitumor activity.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
Address correspondence to Noël Bouck, R.H. Lurie Cancer Center, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, IL 60611. Phone: 312-503-5934; Fax: 312-908-1372; E-mail: n-bouck@nwu.edu
ISSN:0022-1007
1540-9538
DOI:10.1084/jem.188.6.1039